Previous Close | 7.32 |
1-Year Change | 25.56% |
6-Months Change | -43.74% |
3-Months Change | -47.34% |
Moving Avg (50d) | 11.2634 |
Moving Avg (200d) | 10.0252 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.17B |
Beta (3-Years) | 1.95 |
Revenue Growth (ttm) | -38.17% |
Net Profit Margin (ttm) | -29.8% |
Return On Assets (ttm) | -16.18% |
EPS (ttm) | -2.79 |
PE Ratio (ttm) | -2.62 |
Dividend Yield | % |
Asset Description: | Novavax, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-18 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
7.899 | 7.657 | 7.496 | 7.254 | 6.851 | 6.448 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |